InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,464.62
(
-0.16%
)
US TECH 100
19,220.00
(
-0.20%
)
Dow Jones
39,150.33
(
0.04%
)
Brent Oil
84.39
(
0.00%
)
Bitcoin
64,266.59
(
0.28%
)
Post# of 252302
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 834
Posts 119891
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 143879

Thursday, 06/14/2012 12:49:33 PM

Thursday, June 14, 2012 12:49:33 PM

Post# of 252302
Re: Thrice-weekly Copaxone

Do you think patients will have a say? I mean, if they ask for the more convenient formulation.

A small say at most, IMO—I doubt that many MS patients will even know about the new Copaxone option unless they are made aware of it by their neuro.

Moreover, I question whether a 3x per week dosing schedule for a subcutaneous drug is significantly more convenient than a daily one. If the new drug were weekly, that would be a pretty big deal, but thrice-weekly doesn’t gain much in convenience, IMO.

What do you think?

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up